AbbVie Inc. Files 8-K: Senior Notes and Stock Details

Ticker: ABBV · Form: 8-K · Filed: 2025-02-19T00:00:00.000Z

Sentiment: neutral

Topics: debt, filing, financials

Related Tickers: ABBV

TL;DR

ABBV filed an 8-K on Feb 18, 2025, detailing senior notes and common stock. Check for debt maturity and share info.

AI Summary

On February 18, 2025, AbbVie Inc. filed an 8-K report detailing other events and financial statements. The filing includes information about its common stock and various senior notes due in 2027, 2028, 2029, and 2031. The company's principal executive offices are located at 1 North Waukegan Road, North Chicago, IL 60064.

Why It Matters

This filing provides investors with updated information regarding AbbVie's outstanding debt instruments and common stock, which are crucial for assessing the company's financial structure and potential investment risks.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting financial details and does not indicate any unusual or negative events.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are detailed in this 8-K filing?

The filing primarily details information related to AbbVie Inc.'s common stock and various senior notes with different maturity dates (2027, 2028, 2029, 2031), rather than specific operational events.

What is the par value of AbbVie Inc.'s common stock?

The par value of AbbVie Inc.'s common stock is $0.01.

On what date was this 8-K report filed?

This 8-K report was filed on February 19, 2025, with the earliest event reported being February 18, 2025.

What are the maturity dates for the senior notes mentioned in the filing?

The senior notes mentioned have maturity dates in 2027, 2028, 2029, and 2031.

Where are AbbVie Inc.'s principal executive offices located?

AbbVie Inc.'s principal executive offices are located at 1 North Waukegan Road, North Chicago, IL 60064.

From the Filing

0001104659-25-015015.txt : 20250219 0001104659-25-015015.hdr.sgml : 20250219 20250219092224 ACCESSION NUMBER: 0001104659-25-015015 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250218 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250219 DATE AS OF CHANGE: 20250219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 25637670 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm255723d4_8k.htm FORM 8-K false 0001551152 Common Stock, $0.01 Par Value ABBV 0001551152 2025-02-18 2025-02-18 0001551152 us-gaap:CommonStockMember exch:XNYS 2025-02-18 2025-02-18 0001551152 exch:XCHI us-gaap:CommonStockMember 2025-02-18 2025-02-18 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2025-02-18 2025-02-18 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2025-02-18 2025-02-18 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2025-02-18 2025-02-18 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2025-02-18 2025-02-18 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2025-02-18 2025-02-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 18, 2025       ABBVIE INC. (Exact name of registrant as specified in its charter)       Delaware   001-35565   32-0375147 (State of Incorporation)   (Commission File Number)   (IRS Employer Identification Number)         1 North Waukegan Road North Chicago , Illinois 60064-6400 (Address of principal executive offices, including zip code)    ( 847 ) 932-7900   ( Registrant’s telephone number, including area code )       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨   Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 0.750% Senior Notes due 2027   ABBV27   New York Stock Exchang

View on Read The Filing